Literature DB >> 1474396

QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors.

M C Nicklaus1, G W Milne, T R Burke.   

Abstract

Comparative Molecular Field Analysis (CoMFA) has been applied to a study of quantitative structure-activity relationships (QSAR) of conformationally flexible molecules. The relationship between three-dimensional structure and activity of 20 styrene derivatives which inhibit protein-tyrosine kinase was determined. A technique was developed that allows accurate prediction of the inhibitory activity of these molecules and identification in each case of the active conformation. The problem of multiple energetically acceptable conformations was approached in an iterative procedure. Use was made of the varying degrees of symmetry among the molecules. First, CoMFA QSAR models were developed using only those compounds that possess a symmetrical substituent pattern on the phenyl ring. These CoMFA models were then used to select the active conformers of the less symmetrical compounds in the set. Allowing multiple conformers for each compound in the dataset yielded higher crossvalidated r2 values and better predictivity of the QSAR models. Different probe atoms (C+, O-, neutral C) were explored, the O- probe atom exhibiting the highest selectivity in the conformer selection process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1474396     DOI: 10.1007/bf00130399

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  27 in total

Review 1.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

2.  Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells.

Authors:  R Saperstein; P P Vicario; H V Strout; E Brady; E E Slater; W J Greenlee; D L Ondeyka; A A Patchett; D G Hangauer
Journal:  Biochemistry       Date:  1989-06-27       Impact factor: 3.162

3.  Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives.

Authors:  T Shiraishi; T Domoto; N Imai; Y Shimada; K Watanabe
Journal:  Biochem Biophys Res Commun       Date:  1987-08-31       Impact factor: 3.575

4.  The epidermal growth factor receptor and the prognosis of bladder cancer.

Authors:  D E Neal; L Sharples; K Smith; J Fennelly; R R Hall; A L Harris
Journal:  Cancer       Date:  1990-04-01       Impact factor: 6.860

5.  Tyrosine phosphorylation in signal transduction.

Authors:  T M Roberts; D Kaplan; W Morgan; T Keller; H Mamon; H Piwnica-Worms; B Druker; B Cohen; B Schaffhausen; M Whitman
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1988

6.  Synthesis and evaluation of multisubstrate inhibitors of an oncogene-encoded tyrosine-specific protein kinase. 2.

Authors:  C H Kruse; K G Holden; P H Offen; M L Pritchard; J A Feild; D J Rieman; P E Bender; B Ferguson; R G Greig; G Poste
Journal:  J Med Chem       Date:  1988-09       Impact factor: 7.446

7.  Toxication of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and analogs by monoamine oxidase. A structure-reactivity relationship study.

Authors:  G Maret; N el Tayar; P A Carrupt; B Testa; P Jenner; M Baird
Journal:  Biochem Pharmacol       Date:  1990-08-15       Impact factor: 5.858

8.  Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors.

Authors:  A Gazit; P Yaish; C Gilon; A Levitzki
Journal:  J Med Chem       Date:  1989-10       Impact factor: 7.446

9.  Synthesis, ligand binding, QSAR, and CoMFA study of 3 beta-(p-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters.

Authors:  F I Carroll; Y G Gao; M A Rahman; P Abraham; K Parham; A H Lewin; J W Boja; M J Kuhar
Journal:  J Med Chem       Date:  1991-09       Impact factor: 7.446

10.  CoMFA analysis of the interactions of antipicornavirus compounds in the binding pocket of human rhinovirus-14.

Authors:  G D Diana; P Kowalczyk; A M Treasurywala; R C Oglesby; D C Pevear; F J Dutko
Journal:  J Med Chem       Date:  1992-03-20       Impact factor: 7.446

View more
  7 in total

1.  Alignment of flexible molecules at their receptor site using 3D descriptors and Hi-PCA.

Authors:  A Berglund; M C De Rosa; S Wold
Journal:  J Comput Aided Mol Des       Date:  1997-11       Impact factor: 3.686

2.  Structure-activity correlation study of HIV-1 inhibitors: electronic and molecular parameters.

Authors:  S Hannongbua; L Lawtrakul; J Limtrakul
Journal:  J Comput Aided Mol Des       Date:  1996-04       Impact factor: 3.686

3.  A new procedure for improving the predictiveness of CoMFA models and its application to a set of dihydrofolate reductase inhibitors.

Authors:  R T Kroemer; P Hecht
Journal:  J Comput Aided Mol Des       Date:  1995-10       Impact factor: 3.686

4.  Rigorous treatment of multispecies multimode ligand-receptor interactions in 3D-QSAR: CoMFA analysis of thyroxine analogs binding to transthyretin.

Authors:  Senthil Natesan; Tiansheng Wang; Viera Lukacova; Vladimir Bartus; Akash Khandelwal; Stefan Balaz
Journal:  J Chem Inf Model       Date:  2011-04-08       Impact factor: 4.956

5.  Quantitative structure-activity relationship studies of a series of sulfa drugs as inhibitors of Pneumocystis carinii dihydropteroate synthetase.

Authors:  T Johnson; I A Khan; M A Avery; J Grant; S R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

Review 7.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery.

Authors:  Valère Lounnas; Tina Ritschel; Jan Kelder; Ross McGuire; Robert P Bywater; Nicolas Foloppe
Journal:  Comput Struct Biotechnol J       Date:  2013-04-02       Impact factor: 7.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.